Non-Motor Symptoms in Patients with Parkinson’s Disease – Correlations with Inflammatory Cytokines in Serum
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Parkinson's Disease (PD) is the second most common neurodegenerative disorder of the central nervous system. Motor symptoms are the focus of pharmacotherapy, yet non-motor features of the disease (e.g. fatigue, mood disturbances, sleep disturbances and symptoms of anxiety) are both common and disabling for the patient. The pathophysiological mechanisms behind the non-motor symptoms in PD are yet to be untangled. The main objective of this study was to investigate associations between pro-inflammatory substances and non-motor symptoms in patients with PD. METHODS AND MATERIALS: We measured C-reactive protein, interleukin (IL)-6, soluble IL-2 receptor (sIL-2R) and tumor necrosis factor-α (TNF-α) in blood samples from PD patients (n=86) and healthy controls (n=40). Symptoms of fatigue, depression, anxiety and sleeping difficulties were assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT), the Hospital Anxiety and Depression Scale (HAD), and the Scales for Outcome in PD-Sleep Scale respectively. RESULTS: IL-6 was significantly higher in PD patients than in healthy controls. Compared to healthy controls, PD patients displayed significantly higher mean scores on HAD and lower scores on FACIT, thus indicating more severe symptoms as measured with these scales. Within the PD sample, high levels of both sIL-2R and TNF-α were significantly associated with more severe symptoms assessed by means of FACIT and HAD (depression and anxiety subscales). SIL-2-R levels were able to significantly predict FACIT and HAD scores after the effects of age, gender, anti-parkinsonian medications, and severity of motor symptoms were controlled for. DISCUSSION: We suggest that non-motor symptoms in PD patients, such as fatigue and depressive symptoms, might be generated via inflammatory mechanisms. This knowledge might contribute to the development of novel treatment options in PD, specifically targeting non-motor symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Increased levels of IL-6 in PD patients’ serum have been reported in a number of studies [254,255,256]”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [254]
In the citing paper
“proinflammatory cytokines could play a role in the nonmotor symptoms of PD [42]”
From Neuroprotective Effect of Ceftriaxone on MPTP‐Induced Parkinson’s Disease Mouse Model by Regulating Inflammation and Intestinal Microbiota (2021) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822
Interleukin-2: Inception, Impact, and Implications
Smith, K. A. (1988) · Science · doi:10.1126/science.3131876 · Cited by 2,153
Twenty years of research on cytokine-induced sickness behavior
Dantzer, R., & Kelley, K. W. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2006.09.006 · Cited by 1,420
Cytokines and major depression
Schiepers, O. J. G., Wichers, M. C., & Maes, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.11.003 · Cited by 1,235 · cited 5×
“However, there are preliminary clinical trials of MDD patients without PD indicating that NSAIDs as add-on to conventional antidepressants may have beneficial effects on depressive symptoms [42,43].”
InfluentialLiu, Y., Ho, R. C.-M., & Mak, A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.08.003 · Cited by 948
Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (2013) · PsycTESTS Dataset · doi:10.1037/t03589-000 · Cited by 946
Blum-Degena, D., Müller, T., Kuhn, W., Gerlach, M., Przuntek, H., & Riederer, P. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12192-7 · Cited by 801
Müller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001805 · Cited by 794
The Soluble Interleukin-2 Receptor: Biology, Function, and Clinical Application
Rubin, L. A., & Nelson, D. L. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-8-619 · Cited by 602
Neuropsychiatric symptoms in Parkinson's disease
Aarsland, D., Marsh, L., & Schrag, A. (2009) · Movement Disorders · doi:10.1002/mds.22589 · Cited by 557
Peripheral cytokines profile in parkinson’s disease
Reale, M., Iarlori, C., Thomas, A., Gambi, D., Perfetti, B., Di Nicola, M., & Onofrj, M. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2008.07.003 · Cited by 547 · cited 1×
“Peripheral blood monocytes isolated from PD patients produce larger amounts of several cytokines, including tumor necrosis factor alpha (TNF-a), than healthy controls - indicating that the elevated serum levels of cytokines are symptoms of immunological dysregulation, rather than just secondary to the dopaminergic cel…”
Lindqvist, D., Janelidze, S., Hagell, P., Erhardt, S., Samuelsson, M., Minthon, L., Hansson, O., Björkqvist, M., Träskman-Bendz, L., & Brundin, L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.030 · Cited by 524 · cited 1×
“IL-6 is an important cytokine in the innate immune response, and has been found to be elevated in such diverse conditions as suicidal depression [26] and heart disease [27].”
Self-citationAkhondzadeh, S., Jafari, S., Raisi, F., Nasehi, A. A., Ghoreishi, A., Salehi, B., Mohebbi-Rasa, S., Raznahan, M., & Kamalipour, A. (2009) · Depression and Anxiety · doi:10.1002/da.20589 · Cited by 397
Determinants of health-related quality of life in Parkinson’s disease: A systematic review
Soh, S.-E., Morris, M. E., & McGinley, J. L. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.08.012 · Cited by 386
Effect of Psychiatric and Other Nonmotor Symptoms on Disability in Parkinson's Disease
Weintraub, D., Moberg, P. J., Duda, J. E., Katz, I. R., & Stern, M. B. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52219.x · Cited by 381
Association of circulating TNF-α and IL-6 with ageing and parkinsonism
Dobbs, R. J., Charlett, A., Purkiss, A. G., Dobbs, S. M., Weller, C., & Peterson, D. W. (1999) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1999.tb00721.x · Cited by 324
Anti-inflammatory drugs and risk of Parkinson disease: A meta-analysis
Gagne, J. J., & Power, M. C. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d5a4a3 · Cited by 322
Teismann, P., & Ferger, B. (2001) · Synapse · doi:10.1002/1098-2396(200102)39:2<167::aid-syn8>3.0.co;2-u · Cited by 306
Epidemiology of Parkinson’s Disease
(2007) · Parkinson's Disease · doi:10.3109/9781420019223-6 · Cited by 262
Assessment of Sleep and Sleepiness in Parkinson Disease
Marinus, J., Visser, M., van Hilten, J. J., Lammers, G. J., & Stiggelbout, A. M. (2003) · Sleep · doi:10.1093/sleep/26.8.1049 · Cited by 261
Direct economic impact of Parkinson's disease: A research survey in the United Kingdom
Findley, L., Aujla, M., Bain, P. G., Baker, M., Beech, C., Bowman, C., Holmes, J., Kingdom, W. K., MacMahon, D. G., Peto, V., et al. (2003) · Movement Disorders · doi:10.1002/mds.10507 · Cited by 227
Neuroinflammation in the living brain of Parkinson's disease
Ouchi, Y., Yagi, S., Yokokura, M., & Sakamoto, M. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70814-4 · Cited by 209
Müller, T., Blum-Degen, D., Przuntek, H., & Kuhn, W. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1998.tb01736.x · Cited by 195
Antidepressant studies in Parkinson's disease: A review and meta‐analysis
Weintraub, D., Morales, K. H., Moberg, P. J., Bilker, W. B., Balderston, C., Duda, J. E., Katz, I. R., & Stern, M. B. (2005) · Movement Disorders · doi:10.1002/mds.20555 · Cited by 191 · cited 1×
“Depressive symptoms in PD patients can be difficult to treat with conventional antidepressants [41].”
The Role of Inflammatory Cytokines in Cognition and Other Non-Motor Symptoms of Parkinson’s Disease
Menza, M., DeFronzo Dobkin, R., Marin, H., Mark, M. H., Gara, M., Bienfait, K., Dicke, A., & Kusnekov, A. (2010) · Psychosomatics · doi:10.1016/s0033-3182(10)70739-8 · Cited by 180
Scalzo, P., Kümmer, A., Cardoso, F., & Teixeira, A. L. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2009.10.062 · Cited by 175
Sleep disturbances in Parkinson's disease
Menza, M., Dobkin, R. D., Marin, H., & Bienfait, K. (2010) · Movement Disorders · doi:10.1002/mds.22788 · Cited by 165
McKinlay, A., Grace, R. C., Dalrymple-Alford, J. C., Anderson, T., Fink, J., & Roger, D. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2007.05.009 · Cited by 164
Occurrence of depression and anxiety prior to Parkinson’s disease
Jacob, E. L., Gatto, N. M., Thompson, A., Bordelon, Y., & Ritz, B. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.06.014 · Cited by 163
Dinh, W., Füth, R., Nickl, W., Krahn, T., Ellinghaus, P., Scheffold, T., Bansemir, L., Bufe, A., Barroso, M. C., & Lankisch, M. (2009) · Cardiovascular Diabetology · doi:10.1186/1475-2840-8-58 · Cited by 148
Major depressive disorder in Parkinson's disease: a register‐based study
Nilsson, F. M., Kessing, L. V., Sørensen, T. M., Andersen, P. K., & Bolwig, T. G. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.02229.x · Cited by 148
Biological significance of soluble IL‐2 receptor
Caruso, C., Candore, G., Cigna, D., Colucci, A. T., & Modica, M. A. (1993) · Mediators of Inflammation · doi:10.1155/s0962935193000018 · Cited by 130
Towards an understanding of fatigue in Parkinson disease
Hagell, P., & Brundin, L. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.159772 · Cited by 120
Self-citationRees, K., Stowe, R., Patel, S., Ives, N., Breen, K., Clarke, C. E., & Ben-Shlomo, Y. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008454 · Cited by 120
Association of peripheral inflammatory markers with chronic fatigue in a population-based sample
Raison, C. L., Lin, J.-M. S., & Reeves, W. C. (2008) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2008.11.005 · Cited by 114
Barnum, C. J., Eskow, K. L., Dupre, K., Blandino, P., Deak, T., & Bishop, C. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.07.016 · Cited by 112
A neuroimmunological perspective on anxiety disorders
Hou, R., & Baldwin, D. S. (2012) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1259 · Cited by 107
Sairam, K., Saravanan, K. S., Banerjee, R., & Mohanakumar, K. P. (2003) · Brain Research · doi:10.1016/s0006-8993(02)04174-4 · Cited by 106
Rees, K., Stowe, R., Patel, S., Ives, N., Breen, K., Clarke, C. E., & Ben-Shlomo, Y. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008454.pub2 · Cited by 101
Modeling neuroinflammatory pathogenesis of Parkinson’s disease
Barnum, C. J., & Tansey, M. G. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84006-3 · Cited by 99
Schiepers, O. J. G., Wichers, M., & Maes, M. H. J. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.02.001 · Cited by 97
Pålhagen, S., Qi, H., Mårtensson, B., Wålinder, J., Granérus, A., & Svenningsson, P. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5353-6 · Cited by 88
Neuroinflammation and Non-motor Symptoms: The Dark Passenger of Parkinson’s Disease?
Barnum, C. J., & Tansey, M. G. (2012) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-012-0283-6 · Cited by 85
Defective production of interleukin-2 in patients with idiopathic Parkinson's disease
Klüter, H., Vieregge, P., Stolze, H., & Kirchner, H. (1995) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(95)00180-a · Cited by 52
Neuropsychiatric symptoms in Parkinson's disease
Friedman, J. H. (2010) · Movement Disorders · doi:10.1002/mds.23175 · Cited by 16
Cited by
Inflammation and immune dysfunction in Parkinson disease
Tansey, M. G., Wallings, R. L., Houser, M. C., Herrick, M. K., Keating, C. E., & Joers, V. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00684-6 · Cited by 1,382
Oxidative stress, mitochondrial damage and neurodegenerative diseases.
Guo, C., Sun, L., Chen, X., & Zhang, D. (2013) · PubMed · doi:10.3969/j.issn.1673-5374.2013.21.009 · Cited by 1,298
Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight
Bhat, A. H., Dar, K. B., Anees, S., Zargar, M. A., Masood, A., Sofi, M. A., & Ganie, S. A. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.07.025 · Cited by 928
The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis?
Houser, M. C., & Tansey, M. G. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-016-0002-0 · Cited by 588
Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy
Muzio, L., Viotti, A., & Martino, G. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.742065 · Cited by 581
“Along the same lines, high levels of both soluble IL-2 receptor (IL-2R) and TNF-α in blood samples of PD patients were significantly associated with more severe symptoms of the disease (Lindqvist et al., 2012).”
Background
Metadata
- Authors
- Lindqvist, D., Kaufman, E., Brundin, L., Hall, S., Surova, Y., & Hansson, O.
- Affiliations
- Lund University (SE)
- Corresponding author
- Lindqvist, Daniel
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-10-17
- Volume
- 7
- Issue
- 10
- Pages
- e47387
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3474801
- OpenAlex
- W2107646604
- Cited by
- 236
- References
- 48
- Citations by year
- 2026: 14 · 2025: 19 · 2024: 22 · 2023: 19 · 2022: 27 · 2021: 21 · 2020: 17 · 2019: 16 · 2018: 16 · 2017: 13 · 2016: 15 · 2015: 15 · 2014: 16 · 2013: 6
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- Funders
- Lunds Universitet
- Vetenskapsrådet
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, non-motor symptoms, fatigue, depression, anxiety, sleep disorders, inflammatory cytokines, interleukin-6, soluble interleukin-2 receptor, TNF-α, C-reactive protein, neuroinflammation
- MeSH terms
- C-Reactive Protein, Female, Humans, Male, Middle Aged, Motor Activity, Parkinson Disease, Regression Analysis, Tumor Necrosis Factor-alpha, Receptors, Interleukin-2, Interleukin-6, Confounding Factors, Epidemiologic, Case-Control Studies, Cytokines, Inflammation Mediators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.